Filing Flows › Rhythm Pharmaceuticals (RYTM) › Q1 2025
Rhythm Pharmaceuticals (RYTM) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Rhythm Pharmaceuticals (RYTM) reported revenue of $32.7M for the first quarter 2025 (Q1 2025), +26% from a year earlier and -22% from the quarter before. Operating margin was -143.7%, net loss $49.5M (151.4% of revenue).
Rhythm Pharmaceuticals, Q1 2025: revenue $32.7M (+26% year over year), operating margin -143.7%, net loss $49.5M, operating cash flow −$40.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $32.7M | -22% | +26% |
| Operating profit | −$47.0M | — | — |
| Net earnings | −$49.5M | — | — |
| Operating cash flow | −$40.4M | — | — |
What changed
Revenue was $32.7M in Q1 2025, up 26% year over year and down 22% from the previous quarter.
Operating costs exceeded revenue by $47.0M, an operating margin of -143.7%. Total costs fell 52% while revenue rose 26%. The fastest-growing cost line was Cost of revenue (+30%). The quarter ended with a net loss of $49.5M, wider than the previous quarter's $43.3M loss.
Operating cash flow was −$40.4M. Non-cash charges added back $12.9M of share-based compensation. Working capital and other items used $3.7M.
Questions
What was Rhythm Pharmaceuticals' revenue in the first quarter 2025?
Rhythm Pharmaceuticals (RYTM) reported revenue of $32.7M for the first quarter 2025 (Q1 2025), +26% from a year earlier and -22% from the quarter before.
Was Rhythm Pharmaceuticals profitable in the first quarter 2025?
Operating loss was $47.0M (-143.7% of revenue) and net loss $49.5M.